Louis B. Rice, MD
Acknowledgments: The author thanks Martin Blaser, MD, and Steve Czinn, MD, for their helpful advice and perspectives on H. pylori infection.
Potential Financial Conflicts of Interest:Consultancies: Wyeth Pharmaceuticals, Elan Pharmaceuticals, InterMune, Cubist, Pharmacia, Exponential Therapies, Basilea, Bristol-Myers Squibb, Merck and Co., Theravance, Genome Therapeutics, Shire Pharmaceuticals; Honoraria: Wyeth Pharmaceuticals, Elan Pharmaceuticals, Merck and Co.; Grants received: Wyeth Pharmaceuticals, Elan Pharmaceuticals, InterMune.
Requests for Single Reprints: Louis B. Rice, MD, Medical Service 111(W), Louis Stokes Cleveland Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106; e-mail, email@example.com.
For most of the infectious diseases on the wards of the Boston City Hospital in 1937, there was nothing to be done beyond bed rest and good nursing care. Then came the explosive news of sulfanilamide, and the start of the real revolution in medicine. I remember the astonishment when the first cases of pneumococcal and streptococcal septicemia were treated in Boston in 1937. The phenomenon was almost beyond belief. Here were moribund patients, who would surely have died without treatment, improving in their appearance within a matter of hours of being given the medicine and feeling entirely well within the next day or so we became convinced, overnight, that nothing lay beyond reach for the future.
Rice LB. Collateral Damage. Ann Intern Med. 2003;139:523–524. doi: https://doi.org/10.7326/0003-4819-139-6-200309160-00017
Download citation file:
Published: Ann Intern Med. 2003;139(6):523-524.
Gastroenterology/Hepatology, H. Pylori, Infectious Disease, Peptic Disease.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use